How to get Saxenda in the UK

Saxenda is a prescription-only medicine, so every lawful supply runs through a prescriber who has assessed you. The routes are the same three as for any weight-management treatment.

Saxenda is liraglutide, injected once every day. Mounjaro and Wegovy are injected once a week. That is not a detail — it is the difference between fifty-two injections a year and three hundred and sixty-five, and it is the commonest reason people stop.

Escalation is faster to compensate: about four weeks from the 0.6 mg starting dose to 3.0 mg, against sixteen weeks for semaglutide. So the preparation phase is shorter, and the point at which you know whether it is working arrives sooner.

Whether daily suits you is worth deciding before you start rather than discovering in month two. For some people a small daily routine is easier to keep than a weekly event they can forget; for others it is the opposite. Say which you are during the assessment — it is a legitimate factor in choosing between treatments, not a preference to be embarrassed about.

Every weight-management licence has a review point, and Saxenda’s is both the earliest and the most firmly worded.

It says treatment should be discontinued after 12 weeks on the 3.0 mg daily dose if at least 5% of initial body weight has not been lost. Wegovy and Mounjaro are written differently: at their review points "a decision is required on whether to continue", weighing benefit and risk for the individual. Only Saxenda’s is phrased as a discontinuation.

The evidence behind it is that people who have not reached 5% by that point are unlikely to reach a substantially larger loss later. The rule exists to stop someone injecting daily, and paying for it, when the early response suggests this is not their medicine.

Practically: the clock starts when you reach 3.0 mg, not when you start treatment. Know the date, and know that reaching the review without the result is an outcome the licence anticipated rather than a failure.

Liraglutide is off patent, and this is where Saxenda differs from everything else in the category.

Generic liraglutide products are now on the UK register, and the important thing is that **they are not all the same**. Some carry the full weight-management indication — the same BMI criteria as Saxenda and the same 12-week, 5% discontinuation rule. Others are licensed for type 2 diabetes only, at different doses.

That distinction is almost never explained, and it matters: a liraglutide product licensed for diabetes is not a cheaper Saxenda, and asking for "generic liraglutide" without specifying can produce the wrong conversation. Ask about the ones with the weight-management indication.

Why it is worth asking at all: the price difference between a branded and a generic injection in this class is substantial, and cost is a legitimate part of a treatment decision rather than something to leave out of it. If budget is the reason you are hesitating, this is the one place in this category where there is currently a licensed, cheaper answer.

Four checks, two minutes. The pharmacy is on the General Pharmaceutical Council register. It names its superintendent pharmacist. The MHRA distance selling logo links back to the regulator rather than being a picture. And it will not supply without assessing you.

Storage matters more here than for a weekly pen, because you will be handling the medicine every day. Before first use, keep it refrigerated; after first use it has an in-use period, and the patient information leaflet supplied with your pen is the definitive instruction. A pharmacy that cannot tell you how it ships cold-chain medicines is telling you something.